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Abstract  Most  methods  deﬁne  a  limited  number  of  ‘‘target’’  lesions  to  be  measured  and
other ‘‘non-target’’  lesions  to  be  evaluated  qualitatively.  RECIST  criteria  are  the  most  widely
used although  other  criteria  have  been  proposed  that  are  derived  from  them  based  on  size
alone, or  size  and  attenuation.  Modiﬁed  RECIST  (mRECIST)  criteria  only  concern  hepatocellular
carcinoma  and  only  take  into  account  the  viable  portion  (enhanced  after  injection  during  the
arterial phase).  Cheson  criteria  are  more  complex  as  target  lesions  are  deﬁned  differently
depending  on  the  organ  (lymph  nodes,  liver  or  spleen,  other  organs),  and  involve  both  CT  and
PET scans,  as  well  as  the  clinical  examination  and  bone  marrow  biopsy.
© 2014  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Value of imaging for tumour response assessment
Imaging  plays  a  major  role  in  the  objective  assessment  of  tumour  response  to  anticancer
treatments.  Most  methods  used  to  evaluate  treatments  are  based  on  the  measurement  of
lesion  size.  In  1979,  the  World  Health  Organization  (WHO)  proposed  standardised  crite-
ria,  called  the  WHO  criteria,  for  reporting  the  results  of  new  treatments  in  cancer  [1].
The  Response  Evaluation  Criteria  in  Solid  Tumors  (RECIST)  were  subsequently  deﬁned  by
European,  American  and  CanadianCancer  Research  Organisations  in  order  to  unify  the  var-
ious  modiﬁcations  of  the  WHO  criteria  and  provide  standardised  and  simpliﬁed  criteria  for
comparison  between  clinical  trials  [2].  RECIST,  revised  in  2009,  became  the  most  widely
accepted  criteria  for  response  evaluation  for  clinical  trials  in  most  solid  tumours,  with  the
exception  of  malignant  lymphomas.  For  malignant  lymphoma,  the  International  Working
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each  of  these  categories  of  lesions  (Table  1).  The  overall90  
roup  response  criteria  (called  Cheson  criteria)  introduced
n  1999  and  revised  in  2007,  have  been  generally  adopted
3].
In  this  chapter,  we  describe  these  response  criteria
nd  discuss  other  possible  criteria  based  on  size  or  atten-
ation.  The  contribution  of  functional  imaging  in  the
valuation  of  treatment  will  be  evaluated  in  a  different
hapter.
ECIST Criteria
rinciples
hese  criteria  only  apply  to  solid  tumours  and  are  based
n  the  measurement  of  the  longest  diameter  of  a  patient’s
umour  lesions.  They  can  be  applied  using  CT  and  MRI.  Some
uperﬁcial  lesions  can  be  assessed  clinically  or  by  ultrasound
igure 1. Target lesions according to RECIST criteria. Three lesions can
n this patient: a: enlarged lymph node in Barety’s space with shortest d
nd c: nodule in left nephrectomy bed of 42 mm.  The baseline sum of th
r
r
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maging.  Measurements  made  on  standard  radiographs  can
lso  theoretically  be  used.  However,  these  techniques  are
ot  recommended.  It  is  important  to  use  the  same  method
hroughout  patient  monitoring.
The  principle  is  to  draw  up  an  exhaustive  list  of  both  pri-
ary  and  secondary  lesions  before  the  start  of  treatment.
hese  lesions  are  then  followed  up  on  subsequent  examina-
ions  in  order  to  determine  if  they  respond  to  treatment
r  not.  Two  types  of  lesions  are  deﬁned  on  the  baseline
xamination:  target  lesions  (Fig.  1)  and  non-target  lesions
Fig.  2).  Note  that  blood  levels  of  tumour  markers  may
e  included  as  non-target  lesions  (e.g.  CA125  in  ovarian
ancer)  [4]. During  follow-up  examinations,  the  patient’s
esponse  to  treatment  is  determined  by  the  change  in be considered measurable and therefore selected as target lesions
iameter of 46 mm; b: posterior mediastinal mass measuring 71 mm
e diameters for this patient was therefore 46 + 71 + 42 = 159 mm.
esponse  is  a  combination  of  the  above  responses:  complete
esponse,  partial  response,  stable  disease  or  progressive  dis-
ase  (Table  2).  In  order  to  correctly  apply  these  criteria,
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Figure 2. Non-target lesions according to RECIST criteria: a: pleural thickening invading the ribs (arrowhead); b: subcentimetric pulmonary
lesions (circles); c: peripheral septal thickening (circles) and spiculated thickening of bronchovascular sector in contact with a bronchus
(arrowhead) corresponding to lymphangitic carcinomatosis. These lesions cannot be reliably measured and their progression must therefore
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it  is  essential  to  have  the  whole  patient  follow-up  as  the
objective  response  is  deﬁned  in  comparison  with  the  base-
line  (pretreatment)  examination,  whereas  progression  is
deﬁned  in  comparison  with  the  smallest  sum  of  target  lesions
(nadir).
RECIST  criteria  were  updated  in  early  2009  [5],  based  on
an  analysis  of  the  literature  and  simulations  from  a  database
of  >  6500  patients  and  >  18,000  lesions.  The  new  version  is
called  version  1.1  (with  the  previous  version  becoming  1.0).
The  main  changes  were  to  reduce  the  number  of  target
lesions  to  be  measured  and  take  into  account  the  speci-
ﬁcity  of  lymph  nodes  by  measuring  their  short  axis.  Several
examples  are  given  to  clarify  the  expression  unequivocal
progression  of  non-target  lesions.  In  particular,  the  progres-
sion  of  a  single  non-target  lesion  cannot  be  sufﬁcient  to
qualify  for  progression  status.  The  presence  of  new  lesions
must  also  be  unequivocal  for  a  patient  to  be  considered  to
have  progressive  disease.  This  new  version  provides  a  guide
to  the  use  of  PET  for  determining  the  metastatic  nature  of
new  lesions.
Note  that  it  is  not  essential  to  inject  contrast  material
for  the  RECIST  evaluation  if  the  lesions  are  spontaneously
t
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tisible,  as  may  be  the  case  at  certain  anatomical  sites  (lung,
ymph,  bone,  etc.)  and  on  MRI.
imitations of RECIST
ECIST  criteria  have  provided  a  standardised  framework  for
eading  and  interpreting  the  efﬁcacy  of  treatments,  but  are
ll-suited  to  the  evaluation  of  certain  organs  (liver,  bone)
nd  some  treatments.  In  addition,  the  selected  thresholds
−30%  for  a  response  and  20%  for  progression)  were  cho-
en  arbitrarily  without  any  validation  demonstrating  that
hey  reﬂect  patient  outcomes  (e.g.  overall  survival).  The
hresholds  (of  response  or  progression)  for  predicting  dif-
erences  in  survival  in  treated  patients  probably  differ
ccording  to  the  type  of  treatment  and  the  type  of  can-
er  [6].  For  example,  targeted  molecules  such  as  anti-VEGF
r  anti-EGFR  often  induce  only  small  size  changes,  whereas
atient  survival  is  signiﬁcantly  prolonged  [7]. Likewise,
hese  criteria  are  totally  inappropriate  for  assessing  the
esponse  to  image-guided  focal  therapies  (radiofrequency
blation,  chemoembolisation  etc.),  which  often  leave  scars
he  same  size  or  larger  than  the  initial  lesion  [8,9]. Other
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Table  1  Deﬁnitions  and  response  categories  for  each  type  of  lesion  according  to  RECIST  1.1.
Target  lesions  Non-target  lesions  New  lesions
Deﬁnition  Lesions  with  longest
diameter  ≥  10  mm  and  limits  that
are  sufﬁciently  well  deﬁned  for
their  measurement  to  be
considered  reliable
Lymph  nodes:  measurement  of
short  axis,  target  lesion  if
short-axis  measures  ≥  15  mm
RECIST  1.1:  maximum  number  of
selected  target  lesions  5/patient
and  2/organ
Lesions  that  are  too  small
(<  10  mm)
Lesions  for  which  measurement
is  considered  unreliable  as  their
limits  are  difﬁcult  to  deﬁne
(bone  or  leptomeningeal  lesions,
ascites,  pleural  or  pericardial
effusion,  lymphangitic
carcinomatosis  etc.)
Measurable  lesions  not  included
in  the  target  lesions
Lymph  nodes:  measurement  of
short  axis,  non-target  lesion  if
10  mm  ≤  short-axis
diameter  <  15  mm
Levels  of  tumour
markers  >  normal  (if  relevant
and  predeﬁned)
Complete
response  (CR)
Disappearance  of  all  target  lesions
and  all  nodes  with  short
axis  <  10  mm
Disappearance  of  all  non-target
lesions  and  normalisation  of
tumour  marker  levels
No  (no  new
lesion)
Partial  response
(PR)
≥  30  %  decrease  in  the  sum  of
target  lesions  taking  as  reference
the  baseline  sum
No progression  No  (no  new
lesion)
Stable  disease
(SD)
Neither  response  nor  progression  Persistence  of  one  or  more
non-target  lesions  and/or
tumour  marker  levels  >  normal
No (no  new
lesion)
Progressive
disease  (PD)
≥  20  %  increase  in  the  sum  of  target
lesions  taking  as  reference  the
smallest  sum  measured  during
follow-up  (nadir)  and  ≥  5  mm  in
absolute  value
‘Unequivocal’  progression
(assessed  qualitatively)  in  lesion
size  (an  increase  in  size  of  a
single  lesion  is  not  sufﬁcient)
Yes (appearance
of new
unequivocally
metastatic
lesion(s))
The sum of target lesions is deﬁned as the sum of the longest diameters for non-nodal lesions and the short axis for lymph nodes.
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creatment  response  criteria  have  therefore  been  devel-
ped  which  are  based  on  a  different  threshold  of  response
10],  attenuation  measurements  reﬂecting  tumour  necrosis
11],  measurement  of  the  viable  parts  alone  [12],  or  func-
ional  imaging  (perfusion,  diffusion)  [13,14]  and  metabolic
t
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Table  2  Deﬁnition  of  overall  response  according  to  the  respo
Target  lesions  Non-target  lesions  
CR  CR  
CR  SD  
PR  No  PD  
SD  No  PD  
PD  —  
—  PD  
—  —  
CR: complete response; PR: partial response; SD: stable disease; PD: priteria  (PERCIST  criteria  or  new  PET  markers)  [15].  In  addi-
ion,  speciﬁc  criteria  for  certain  diseases  or  treatments
ave  also  been  developed  by  working  groups,  such  as  those
or  mesothelioma  [16]  and  immunotherapy  (Immune-related
esponse  Criteria  [irRC])  [17].
nse  of  each  lesion  category.
New  lesions  Overall  response
No  CR
No  PR
No  PR
No  SD
—  PD
—  PD
Yes  PD
rogressive disease.
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Other evaluation criteria for solid tumours
Other criteria based on size
Thiam  et  al.  [10]  carried  out  a  statistical  analysis  in  order  to
determine  a  threshold  for  size  evaluation  that  best  reﬂects
the  beneﬁt  of  targeted  therapies  in  terms  of  progression-
free  survival  (PFS)  in  patients  treated  with  anti-angiogenic
therapy  for  metastatic  kidney  cancer.  A  decrease  of  at  least
10%  in  the  sum  of  the  longest  diameters  was  found  to  be  the
threshold  that  best  distinguishes  between  responders  and
non-responders.  The  value  of  this  −10%  response  threshold
was  conﬁrmed  in  two  studies  on  independent  populations  of
patients  with  metastatic  renal  cell  carcinoma  [18,19], and
also  in  metastatic  urothelial  cancer  [20].  It  remains  to  be
seen  if  this  threshold  is  applicable  to  other  cancers  treated
with  targeted  therapy.
Criteria based on size and density
Signiﬁcant  changes  in  tumour  density  (attenuation)  mea-
sured  by  CT  are  observed  during  treatment,  which  are
attributed  to  tumour  necrosis  although  this  is  rarely  necrosis
according  to  the  histological  deﬁnition.  It  would  probably
be  more  accurate  to  speak  of  tumour  devascularisation.
In  fact,  CT  scan  enhancement,  or  attenuation  after  injec-
tion  of  contrast  material,  is  related  to  the  amount  of
blood  reaching  the  tumour  and  therefore  the  quantity
and  function  of  tumour  blood  vessels.  Choi  criteria  [11]
were  the  ﬁrst  to  introduce  this  new  CT  parameter  for
the  evaluation  of  treatments,  based  on  the  experience  of
the  effect  of  imatinib  in  gastrointestinal  stromal  tumors
(GIST).
Similarly,  in  the  case  of  image-guided  focal  therapies
(radiofrequency  ablation,  embolisation  etc.),  and  in  partic-
ular  for  hepatocellular  carcinoma  (sometimes  also  extended
to  liver  metastases),  the  evaluation  of  attenuation  is  used
to  estimate  the  portion  of  the  tumour  taking  up  contrast
agent  and  considered  to  reﬂect  the  remaining  viable  por-
tion.
Modiﬁed Choi criteria, SACT, MASS, etc.
Choi  et  al.  [11]  developed  evaluation  criteria  to  detect
the  efﬁcacy  of  imatinib  in  patients  with  gastrointestinal
stromal  tumours  (GIST).  Imatinib  is  known  to  induce  sig-
niﬁcant  tumour  necrosis,  which  may  be  accompanied  by  a
paradoxical  increase  in  tumour  size  and  therefore  simulate
progression.  Choi  criteria  combine  changes  in  tumour  atten-
uation  expressed  in  Hounsﬁeld  units  (HU)  and/or  size  to
determine  the  tumour  response  (Fig.  3).  According  to  Choi
et  al.,  a  PR  is  deﬁned  as  a  decrease  ≥  10%  in  the  sum  of
sizes  OR  a  decrease  ≥  15%  in  the  mean  attenuation  of  target
lesions  measured  by  CT  with  injection  of  contrast  mate-
rial,  whereas  PD  is  deﬁned  as  a  ≥  10%  increase  in  size  not
complying  with  the  PR  criteria  for  density.  In  GIST  patients
treated  with  imatinib,  Choi  criteria  showed  a  signiﬁcantly
better  correlation  with  survival  rates  than  RECIST  criteria
[21].
These  criteria  were  applied  to  other  targeted  can-
cer  therapies,  most  often  in  metastatic  kidney  cancer,
but  with  contradictory  results  [18,22,23].  Multiple  variants
c
o
o
f Cheson  693
ave  also  been  proposed.  Modiﬁed  Choi  criteria  propose
hat  the  response  be  deﬁned  by  a  reduction  in  size  AND
rather  than  OR)  attenuation  [24].  SACT  criteria  [25]  pro-
ose  the  measurement  of  mean  attenuation  over  the
hole  tumour  volume,  distinguishing  lung  lesions  from
hose  at  other  sites.  MASS  criteria  [26]  integrate  assess-
ents  of  the  morphological  changes  in  tumours  during
reatment,  such  as  the  appearance  of  ‘‘marked  central
ecrosis’’  (>  50%  of  an  initially  solid  area  transformed  into
uid  attenuation)  or  ‘‘central  ﬁlling’’  (transformation  of
 previously  necrotic  area  into  a  solid  portion).  However,
hese  criteria  are  much  more  complicated  than  RECIST
r  Choi  criteria,  and  introduce  subjective  parameters  and
re  therefore  difﬁcult  to  apply  in  routine  clinical  prac-
ice.
iver lesions: EASL and mRECIST criteria
he  evaluation  of  the  efﬁcacy  of  a  treatment  on  liver  lesions
oses  speciﬁc  problems.
Firstly,  the  injection  of  contrast  and  the  acquisition  time
fter  injection  (arterial,  portal  venous  and  delayed  phases)
igniﬁcantly  alter  the  visibility  and  therefore  the  size  of
iver  lesions.  This  is  further  complicated  by  the  fact  that
he  phase  during  which  the  lesion  is  most  visible  may  vary
s  a  result  of  treatment.  Lesions  may  also  appear  during
reatment  because  of  their  increased  visibility  following  the
evascularisation  of  lesions.  This  problem  is  less  pronounced
n  MRI  where  lesions  can  often  be  measured  on  sequences
ithout  injection  of  contrast.
Secondly,  liver  lesions  and  especially  hepatocellular
arcinoma  (HCC)  are  often  treated  by  focal  therapy
radiofrequency  ablation,  chemoembolisation  etc.).  These
herapies  cause  morphological  changes  in  the  lesions  and
eave  scars,  so  that  their  efﬁcacy  cannot  be  assessed  accord-
ng  to  size.  Since  2000,  the  European  Association  for  the
tudy  of  the  Liver  (EASL)  and  the  American  Association  for
he  Study  of  Liver  Disease  (AASLD)  admitted  criteria  that
nly  take  into  account  changes  in  the  viable  portion  (deﬁned
s  the  portion  enhanced  after  injection  during  the  arterial
hase)  to  assess  the  efﬁcacy  of  focal  therapies.  The  cur-
ently  most  widely  used  criteria  were  adapted  from  RECIST
nd  EASL  criteria,  and  are  called  mRECIST  criteria  [12].  The
esponse  of  target  lesions  (Fig.  4)  is  evaluated  from  the  per-
entage  change  in  the  sum  of  the  diameters  of  the  viable
ortions  (portions  enhanced  during  the  arterial  phase).  For
esions  with  atypical  enhancement  dynamics  (without  arte-
ial  enhancement),  conventional  RECIST  criteria  must  be
pplied  (Table  3).
imitations of criteria measuring attenuation
here  are  several  limitations  to  the  use  of  attenuation-based
riteria.  Acquisition  times  after  injection  of  intravenous
ontrast  agent  must  be  respected  in  order  not  to  introduce
seudo-changes  related  to  the  method  used  rather  than  a
hange  due  to  tumour  therapy.  Furthermore,  the  injection
f  contrast  media  may  not  be  possible  in  a  certain  number
f  cancer  patients,  who  often  combine  several  risk  factors
or  renal  failure.
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Figure 3. Target lesions according to CHOI criteria. Three lesions may be considered measurable according to CHOI criteria in this patient:
a: enlarged subcarinal lymph node of 33 mm and 77 HU; b: lung nodule of 15 mm and 81 HU; c: peritoneal nodule of 51 mm  and 50 HU. The
sum of the lengths of target lesions measured before treatment was 33 + 15 + 51 = 99 mm. The mean attenuation of target lesions measured
before treatment was (77 + 81 + 50)/3 = 69 HU. After treatment, mainly a change in target lesion attenuation was observed: d: the subcarinal
lymph node measured 34 mm and 63 HU; e: the pulmonary nodule measured 12 mm and 40 HU; f: the peritoneal nodule measured 50 mm and
38 HU. The sum of the lengths of target lesions after treatment was 34 + 12 + 50 = 96 mm with a change of −3%. The mean of the attenuation
of target lesions after treatment was (63 + 40 + 38)/3 = 47 HU i.e. a change of −32%. The patient was a responder according to Choi criteria
as the mean attenuation decreased by more than 15%.
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Figure 4. a: lesion of the segment VIII of the liver compatible with hepatocellular carcinoma seen as a hypervascular nodule on the
arterial phase of the Gadolinium-enhanced T1-weighted fat-saturated sequence. Alpha-foetoprotein levels were 1518 ng/mL. As the whole
of the lesion was enhanced, it was measured according to mRECIST criteria to be 24 mm; b: gadolinium-enhanced T1-weighted fat-saturated
sequence on the arterial phase, performed three weeks after radiofrequency ablation of the nodule, showing the complete disappearance
of the arterial contrast. This was a complete response according to mRECIST criteria.
Table  3  Deﬁnitions  and  response  categories  for  hepatocellular  carcinoma  according  to  mRECIST.
Target  lesions  Non-target  lesions  New  lesions
Deﬁnition  HCC
longest  diameter  ≥  10  mm
nodular  (clear  boundaries,
non-inﬁltrating)
enhancement  on  arterial  phase  on  CT  or
MRI
For  other  sites:  id.  RECIST
HCC: lesion  too  small  (<
10  mm),  inﬁltrating  or
atypical  enhancement
(non-arterial)
For  other  sites:  id.  RECIST
Complete
response  (CR)
Disappearance  of  any  intratumoral
arterial  enhancement  during  in  target
lesions
Id. RECIST  No  (no  new  lesion)
Partial  response
(PR)
≥  30%  of  the  sum  of  the  diameters  of
viable  portions  (enhancement  on  arterial
phase)  of  target  lesions  taking  as
reference  the  baseline  sum
Id. RECIST  No  (no  new  lesion)
Stable  disease
(SD)
Neither  response  nor  progression  Id.  RECIST  No
(no  new  lesion)
Progressive
disease  (PD)
≥  20  %  of  the  sum  of  the  diameters  of
viable  (enhancing)  portions  of  target
lesions  taking  as  reference  the  smallest
sum  of  the  diameters  of  viable  portions
of  target  lesions  recorded  since  the  start
of  treatment  (nadir)
Id.  RECIST  Yes  (appearance  of  new  lesion(s)
for  which  the  diagnosis  of  HCC  is
unequivocala)
Yes  (appearance  of  new  lesion(s)
for  which  the  diagnosis  of  a
metastatic  lesion  is
unequivocala)
HCC: hepatocellular carcinoma.
a A new liver nodule is classiﬁed as HCC, and will therefore be declared as a progression, when its longest diameter is ≥ 10 mm  and it
presents the typical enhancement of HCC on dynamic imaging, i.e. contrast uptake during the arterial phase with portal vein/delayed
phase washout. ≥ 10 mm lesions which do not exhibit typical enhancement dynamics may be diagnosed as HCC if they increase of ≥
of pr
t
(
a10 mm on subsequent examinations. In this latter case, the date 
the lesion.
Evaluation criteria of tumour response in
lymphomas: Cheson criteria (International
Working Group or IWG Criteria)In  1999,  an  international  working  group  consisting  of  cli-
nicians,  radiologists  and  pathologists,  who  were  experts  in
e
i
i
togression used a posteriori will be the date of ﬁrst detection of
he  evaluation  and  management  of  non-Hodgkin  lymphoma
NHL)  patients,  published  recommendations  for  the  evalu-
tion  of  the  treatment  response  and  parameters  of  clinical
fﬁcacy  in  this  disease  [27].  However,  these  criteria  had  lim-
tations,  in  particular  a  high  variability,  the  failure  to  take
nto  account  PET,  immunohistochemistry  and  ﬂow  cytome-
ry  and  the  failure  to  take  into  account  non-nodal  disease.
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196  
ew  criteria  (IWG  2007)  were  therefore  deﬁned  in  2007  that
ere  applied  to  NHL  and  also  Hodgkin’s  disease  [3].
The  initial  assessment  includes:
clinical  examination;
bone  marrow  biopsy;
cervical,  thoracic,  abdominal  and  pelvic  CT-scan;
PET  for  lymphomas  that  are  frequently  hypermetabolic
(i.e.  diffuse  large  B-cell  non-Hodgkin’s  lymphoma  or
Hodgkin’s  disease).
On CT,  the  target  lesion  is  measured  along  two  perpen-
icular  axes  in  order  to  determine  the  sum  of  the  product
f  the  diameters  (longest  diameter  ×  short-axis  diameter)
Fig.  5).
Assessment  examinations  are  used  to  deﬁne  the
esponse,  which  is  a  complex  combination  of  imaging  ﬁnd-
ngs  (CT  and  PET),  clinical  examination  and  bone  marrow
iopsy.
Today,  new  PET  response  criteria  (Deauville  criteria  2009,
enton  criteria  2011),  based  on  changes  in  SUV  by  FDG-
ET  are  being  evaluated  to  optimise  the  assessment  of
arly  response  during  treatment  and  the  end-of-treatment
esponse.  Whole-body  MRI  may  also  help  complete  these
valuation  criteria  (Table  4).
ractical applications and perspectives
hould  these  criteria  be  used  for  the  daily  monitoring  of
atients?  It  is  important  to  bear  in  mind  that  these  criteria
ere  developed  in  order  to  compare  the  efﬁcacy  of  dif-
erent  drugs  during  clinical  trials.  However,  they  may  also
e  useful  for  the  radiologist  and  oncologist  as  a  guide  to
nterpreting  the  changes  observed  during  treatment.  They
eﬁne  the  lesions  that  should  be  monitored  and  also  those
or  which  measurements  are  unreliable.  They  provide  a
ramework  for  reading  examinations  and  writing  reports,
nvolving  the  measurement  of  the  same  lesions  on  succes-
ive  examinations,  and  an  overall  conclusion,  to  improve
eadability  for  clinicians.  Reproducible,  objective  and  quan-
itative  criteria  are  needed  to  deﬁne  a  common  language
etween  radiologists  and  clinicians,  so  that  they  can  make
nformed  treatment  decisions.
However,  these  two  settings  have  different  require-
ents:  assessments  during  clinical  trials  require  arbitrary
tandardisation  in  order  to  compare  the  efﬁcacy  of  different
rugs  whereas  assessments  during  routine  clinical  practice
hould  reﬂect  the  future  clinical  beneﬁt  for  patients.  These
riteria  must  be  rigorously  and  inﬂexibly  applied  during  clini-
al  trials.  In  routine  clinical  practice,  criteria  are  very  useful
s  a  basis  for  interpretation,  but  caution  should  be  exer-
ised  about  the  conclusions  given  in  reports.  The  response
r  radiological  progression  is  not  the  only  factor  impact-
ng  the  therapeutic  decision,  as  other  factors  such  as  the
linical  and  biological  response  or  progression,  toxicity,  and
lso  the  presence  or  absence  of  other  treatment  options
hould  also  be  considered.  The  conclusion  of  the  imaging
rocedure  should  not  place  clinicians  in  a  situation  forcing
hem  to  make  a  certain  therapeutic  decision.  It  can  be  difﬁ-
ult  to  explain  to  patients  that  a  certain  treatment  must  be
ontinued  or  discontinued  if  the  conclusion  of  the  imaging
rocedure  suggests  the  opposite.
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Bone  lesions  are  among  the  most  difﬁcult  to  assess
nd  none  of  the  proposed  criteria  is  quite  satisfactory  for
heir  follow-up  during  treatment  outside  the  special  case
f  lymphomas,  where  MRI  may  help  assess  bone  marrow
nvolvement.  [28].  Bone  metastases  are  traditionally  eval-
ated  by  a  bone  scan,  but  this  examination  is  not  very
ensitive  to  changes  [29].  Their  evaluation  is  complicated
y  the  fact  they  exist  in  lytic,  sclerotic,  or  mixed  forms
ith  possible  transition  from  the  ﬁrst  to  the  second  form
uring  treatment.  Moreover,  sclerotic  lesions  may  fail  to
isappear  even  when  ‘‘sterilised’’  and  false  lesions  may
ppear  when  they  become  more  sclerotic  during  treat-
ent.
Overall,  although  the  above-described  criteria  are  very
seful,  the  problem  of  evaluating  the  efﬁcacy  of  treatments
as  not  yet  been  fully  resolved.  Many  new  criteria  continue
o  be  proposed  in  the  literature  to  evaluate  therapies.  In  the
uture,  researchers  must  focus  on  demonstrating  that  they
redict  clinical  beneﬁt,  so  they  are  really  useful  for  ther-
peutic  decision-making.  However,  it  is  difﬁcult  to  deﬁne
riteria  that  are  suitable  for  all  cancers  and  all  therapies.
he  question  should  be  asked  whether  the  future  lies  in  gen-
ral  criteria  with  known  and  controlled  limitations,  or  with
ultiple  speciﬁc  criteria  for  each  clinical  setting.  It  is  up
o  the  imaging  community  to  continue  research  and  answer
his  question.
TAKE-HOME  MESSAGES
• The  evaluation  of  the  response  to  treatment  during
clinical  trials  does  not  meet  the  same  needs  as  in
routine  clinical  practice.
• RECIST  criteria  measure  lesions  in  their  longest
diameter,  except  for  lymph  nodes  that  are  measured
in  their  short  axis.
• mRECIST  criteria  only  measure  the  enhanced  (viable)
portion  of  lesions.
• Cheson  criteria  distinguish  between  lymph  nodes,
liver  and  spleen  and  other  organs,  and  both  CT  and
PET  are  used.
ase reports
uiz 1
linical  history
r.  D.,  aged  58,  with  a  history  of  nephrectomy  four
ears  previously  for  clear  cell  carcinoma,  is  seen  by  the
ncologist  after  the  discovery  of  multiple  metastatic
esions.  The  patient  will  be  included  in  a  clinical  trial  with
ssessment  using  RECIST  criteria  (Fig.  6).
uestions
.  Which  of  the  following  examinations  are  recommended
or  the  baseline  evaluation  of  the  disease  using  RECIST  crite-
ia?
a.  Chest  radiograph.
.  Liver  ultrasound.
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Figure 5. Target and non-target lesions according to CHESON criteria. Four lesions may be selected as target lesions in this patient: a:
enlarged lymph node in Barety’s space of 36 × 22 = 792 mm2; b: enlarged subcarinal node of 62 × 38 = 2356 mm2; c: enlarged coeliac node of
81 × 46 = 3726 mm2; d: splenic lesion of 18 × 16 = 288 mm2. The sum of the products is 792 + 2356 + 3726 + 288 = 7162 mm2. Three lesions can
be chosen as non-target lesions: b: right pleural effusion; e: cluster of enlarged mesenteric lymph nodes; f: enlarged spleen.
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Table  4  Deﬁnitions  and  categories  of  response  for  each  type  of  lesion  according  to  IWG  2007.
Lymph  nodes  Liver,  spleen,  others
Deﬁnition
Target  lesions:  measured  in  two
perpendicular  axes  =  longest
diameter  (long  axis)  and  their
longest  perpendicular  (short
axis).  The  sum  of  the  products  of
the  diameters  is  deﬁned
(  long-axis
diameter  ×  short-axis  diameter
in  mm2)
Up  to  6  lesions/patient,
representing  the  largest  possible
number  of  anatomical  sites,  with
a  preference  for  the  largest
lesions  and  mediastinal  and
retroperitoneal  sites
Non-target  lesions:  measurable
lesions  not  selected  as  targets
and  non-measurable  lesions
Target  lesions:  longest
diameter  >  15  mm
OR  short  axis  >  10  mm
Extra-nodal  target  lesions:  longest
diameter  ≥  10  mm
Target  hepatic  or  splenic  lesions:  two
perpendicular  axes  ≥  10  mm
Non-target  lesions
Bone  lesions
Cutaneous  or  pulmonary
lymphangitis
Enlarged  liver  or  spleen  (measured
by  CT)
Pleural,  pericardial  or  peritoneal
effusion
grouped  lesions
irradiated  lesions
Lesions  detected  during  the  clinical
examination
(apart  from  enlarged)
Complete  response  (CR)
Bone  marrow  biopsy  should  be
Negative  on  the  control  biopsy
If  doubtful,  negative  on
immunohistochemistry
All  lesions  with  a  longest  diameter
≤  15  mm  or  short  axis  ≤  10  mm
Not  palpable  during  the  clinical
examination
No  visible  nodule  on  imaging
And  disappearance  of  all  non-nodal  target  lesions
Or  in  case  of  hypermetabolic  disease  on  the  baseline  PET  scan,  negative
PET  scan  whatever  the  appearance  of  lesions  on  CT
Partial  response  (PR)  ≥  50  %  of  SPD  of  target  lesions  ≥  50  %  of  SPD  of  target  lesions  (or
longest  diameter  if  a  single  nodule)
No  clinically  enlarged  liver  or  spleen
or
In  the  case  of  hypermetabolic  lesions  on  the  baseline  PET  scan,
persistence  of  at  least  one  PET-positive  site  without  progression  of  other
lesions  on  CT
Stable  disease  (SD)  No  response  nor  progression
Progressive  disease  (PD)  or
recurrence
Bone  marrow  biopsy
Recurrence  of  bone  marrow
inﬁltration
Detection  of  (a)  new  lesion(s)  with
longest  diameter  >  15  mm
or
≥  50  %  of  the  SPD  of  at  least  one
nodal  lesion  taking  as  reference
the  smallest  sum  measured  during
follow  up  (nadir);  if  it  is  a  lymph
node  with  previous  short-axis
diameter  <  10  mm,  it  must  reach  a
size  ≥  15  ×  15  mm  or  ≥  15  mm  in
longest  diameter
or
≥  50%  of  longest  diameter  of  a
node  that  previously  had  a
short-axis  diameter  ≥  10  mm
≥  50  %  of  the  SPD  of  at  least  one
splenic  or  hepatic  lesion  taking  as
reference  the  smallest  sum  measured
during  follow-up  (nadir)
In  case  of  hyper-metabolism  on  the  baseline  PET  scan,  lesions  that  are
newly  detected  by  CT  must  also  be  hypermetabolic;  conversely,  any  new
lesion  detected  on  the  PET  scan  must  be  conﬁrmed  by  CT
Modiﬁed from Cheson 1999.
SPD: sum of the products of the diameters; PET: positron emission tomography; CT: computed tomography.
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a
b
c
d
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c.  X-ray  computed  tomography  (CT).
d.  Magnetic  resonance  imaging  (MRI).
2.  Which  of  the  following  lesions  seen  on  images  (Fig.  6)
may  be  included  as  RECIST  1.1  target  lesions?
.  Enlarged  cervical  nodes  of  13  mm  short  axis  (Fig.  6a).
.  Pulmonary  lesions  of  39  and  30  mm  (Fig.  6b).
.  Left  adrenal  lesion  of  30  mm  (Fig.  6c).
A
1
Figure 6. Metastatic lesions detected by CT. a: enlarged cervical nod
and 30 mm; c: left adrenal lesion of 30 mm; d: enlarged interaortocaval
left external iliac lymph node of 21 mm. Cheson  699
.  Enlarged  inter-aorto-caval  node  of  24  mm  (Fig.  6d).
.  Lesion  of  right  iliac  bone  of  54  mm  (Fig.  6e).
.  Enlarged  left  external  iliac  lymph  node  of  21  mm  (Fig.  6f).nswers
.  a.  Chest  radiograph:  wrong.
b.  Liver  ultrasound:  wrong.
es with short-axis diameter of 13 mm; b: pulmonary lesions of 39
 node of 24 mm; e: lesion of right iliac bone of 54 mm;  f: enlarged
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c.  X-ray  computed  tomography  (CT):  right.
d.  Magnetic  resonance  imaging  (MRI):  right.
2.  A  total  of  up  to  ﬁve  targets  are  required:
.  Enlarged  cervical  nodes  with  short-axis  diameter  of
13  mm:  wrong.  A  node  can  only  be  deﬁned  as  a  target
lesion  if  its  short-axis  diameter  ≥  15  mm.
.  Pulmonary  lesions  of  39  and  30  mm:  right.  There  may  be
other  lung  lesions  measuring  ≥  10  mm  but  not  more  than
two  targets  can  be  selected  per  organ..  Left  adrenal  lesion  of  30  mm:  right.  It  measures  ≥  10  mm.
.  Enlarged  inter-aorto-caval  node  of  24  mm:  right.  The
short-axis  diameter  of  this  node  is  ≥  15  mm.
M
l
igure 7. Metastatic lesions detected by CT. All the lesions were hypeL.  Fournier  et  al.
.  Lesion  of  right  iliac  bone  of  54  mm:  wrong.  Bone  lesions
are  non-target  lesions.
.  Enlarged  left  external  iliac  lymph  node  of  21  mm:
right.  The  short-axis  diameter  of  this  node  is  ≥
15  mm.
uiz 2
linical  history
s.  S.,  aged  69  years,  is  followed  up  for  diffuse  large  B-cell
ymphoma  and  enrolled  in  a  clinical  trial  (Figs.  7  and  8).
rmetabolic on the PET scan (images not shown).
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Figure 8. Change in lesions after four months of treatment.
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a
b
c
dQuestions
1.  Which  examinations  should  be  performed  during  the  base-
line  evaluation  to  implement  Cheson  criteria?
a.  Clinical  examination.
b.  Chest  radiograph.
c.  Cervical,  thoracic,  abdominal  and  pelvic  CT.
d. 18F-choline  PET-CT.
e. 18FDG  PET-CT.
2.  The  sum  of  measured  target  lesions  was  1260  mm2:
a.  The  patient  has  a  complete  response  (CR).
b.  The  patient  has  a  partial  response  (PR).
c.  The  patient  has  stable  disease  (SD).
d.  The  patient  has  progressive  disease  (PD).
e.  We  cannot  answer.
enswers
.  What  examinations  should  be  performed  during  the  base-
ine  evaluation  to  implement  Cheson  criteria?
.  Clinical  examination:  right.  Lesions  detected  during  the
clinical  examination  are  classiﬁed  as  non-target  lesions.
.  Chest  radiograph:  wrong.  This  examination  is  not  indi-
cated.
.  Cervical,  thoracic,  abdominal  and  pelvic  CT:  right.  This
examination  is  used  for  the  assessment  of  disease  exten-
sion  and  follow-up.
. 18F-choline  PET-CT:  wrong.  This  examination  is  indicated
in  prostate  cancer.
. 18F-FDG  PET-CT:  right.  Diffuse  large  B-cell  lymphomas  are
often  hypermetabolic.  PET  must  be  performed  before
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the  start  of  treatment  in  order  to  subsequently  perform
follow-up  of  lesions  taking  up 18F-FDG.
2.  On  the  baseline  imaging,  the  sum  of  products
f  target  lesions  as  required  by  Cheson  criteria  was
[23  ×  17]  +  [14  ×  10]  +  [53  ×  40]  +  [58  ×  43])  =  5145  mm2.  The
um  of  target  lesions  measured  after  four  months  of  treat-
ent  was  1260  mm2.
a.  The  patient  has  a  complete  response  (CR):  wrong.  Lymph
node  lesions  with  longest  diameter  ≥  15  mm  persist  and
the  extranodal  lesion  (lung)  has  not  disappeared.
.  The  patient  has  a  partial  response  (PR):  right.  The
patient  has  a  partial  response  as  the  post-treatment
change  in  the  sum  of  the  products  of  diameters  with  ref-
erence  to  baseline  =  (1260  −  5145)/5145  ×  100  =  −75%,
i.e.  a  decrease  ≥  50%.
c.  The  patient  has  stable  disease  (SD):  wrong.  See  above.
.  The  patient  has  progressive  disease  (PD):  wrong.  See
above.
.  We  cannot  answer.  wrong.  See  above.
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